Wenda Liu , Kezhou Xia , Kai Tong , Xinghan Huang, Zhun Wei, Zicheng Wei, Weichun Guo
{"title":"RNF207通过KCNQ1介导的ERK/MEK信号通路激活促进骨肉瘤的增殖、迁移和侵袭","authors":"Wenda Liu , Kezhou Xia , Kai Tong , Xinghan Huang, Zhun Wei, Zicheng Wei, Weichun Guo","doi":"10.1016/j.intimp.2025.115482","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Ring finger protein 207 (RNF207) is an E3 ubiquitin ligase that regulates the stability and activity of target proteins via ubiquitination and non-proteolytic mechanisms. However, its role in osteosarcoma pathogenesis and association with patient prognosis remain poorly understood.</div></div><div><h3>Methods</h3><div>We integrated bioinformatics analyses of public databases with assayal validation in osteosarcoma cell lines and clinical tissue samples to assess RNF207 expression and its prognostic significance. Functional assays were performed to evaluate the impact of RNF207 knockdown or overexpression on osteosarcoma cell proliferation, migration, and invasion. Mechanistic insights were investigated through transcriptomic profiling, mass spectrometry, and co-immunoprecipitation assays. Finally, subcutaneous xenograft models were employed to validate RNF207's role in osteosarcoma progression in vivo.</div></div><div><h3>Results</h3><div>RNF207 was significantly upregulated in osteosarcoma cells and clinical specimens and correlated with adverse clinical outcomes. Genetic silencing of RNF207 suppressed osteosarcoma cell proliferation, migration, and invasion, whereas its overexpression enhanced these malignant phenotypes. Furthermore, RNF207 knockdown attenuated tumor growth in subcutaneous xenograft models. Mechanistically, RNF207 facilitated ubiquitin-mediated degradation of KCNQ1, thereby potentiating MAPK signaling pathway activation.</div></div><div><h3>Conclusion</h3><div>Clinically, elevated RNF207 expression in osteosarcoma patients serves as a biomarker for aggressive disease and unfavorable prognosis. Functionally, RNF207 drives osteosarcoma progression in vitro and in vivo by ubiquitinating and degrading KCNQ1 to hyperactivate MAPK signaling. These findings identify RNF207 as a novel therapeutic target and prognostic marker for osteosarcoma.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"165 ","pages":"Article 115482"},"PeriodicalIF":4.7000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"RNF207 promotes the proliferation, migration and invasion of osteosarcoma through KCNQ1 mediated activation of ERK/MEK signaling pathway\",\"authors\":\"Wenda Liu , Kezhou Xia , Kai Tong , Xinghan Huang, Zhun Wei, Zicheng Wei, Weichun Guo\",\"doi\":\"10.1016/j.intimp.2025.115482\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Ring finger protein 207 (RNF207) is an E3 ubiquitin ligase that regulates the stability and activity of target proteins via ubiquitination and non-proteolytic mechanisms. However, its role in osteosarcoma pathogenesis and association with patient prognosis remain poorly understood.</div></div><div><h3>Methods</h3><div>We integrated bioinformatics analyses of public databases with assayal validation in osteosarcoma cell lines and clinical tissue samples to assess RNF207 expression and its prognostic significance. Functional assays were performed to evaluate the impact of RNF207 knockdown or overexpression on osteosarcoma cell proliferation, migration, and invasion. Mechanistic insights were investigated through transcriptomic profiling, mass spectrometry, and co-immunoprecipitation assays. Finally, subcutaneous xenograft models were employed to validate RNF207's role in osteosarcoma progression in vivo.</div></div><div><h3>Results</h3><div>RNF207 was significantly upregulated in osteosarcoma cells and clinical specimens and correlated with adverse clinical outcomes. Genetic silencing of RNF207 suppressed osteosarcoma cell proliferation, migration, and invasion, whereas its overexpression enhanced these malignant phenotypes. Furthermore, RNF207 knockdown attenuated tumor growth in subcutaneous xenograft models. Mechanistically, RNF207 facilitated ubiquitin-mediated degradation of KCNQ1, thereby potentiating MAPK signaling pathway activation.</div></div><div><h3>Conclusion</h3><div>Clinically, elevated RNF207 expression in osteosarcoma patients serves as a biomarker for aggressive disease and unfavorable prognosis. Functionally, RNF207 drives osteosarcoma progression in vitro and in vivo by ubiquitinating and degrading KCNQ1 to hyperactivate MAPK signaling. These findings identify RNF207 as a novel therapeutic target and prognostic marker for osteosarcoma.</div></div>\",\"PeriodicalId\":13859,\"journal\":{\"name\":\"International immunopharmacology\",\"volume\":\"165 \",\"pages\":\"Article 115482\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International immunopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1567576925014730\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567576925014730","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
RNF207 promotes the proliferation, migration and invasion of osteosarcoma through KCNQ1 mediated activation of ERK/MEK signaling pathway
Background
Ring finger protein 207 (RNF207) is an E3 ubiquitin ligase that regulates the stability and activity of target proteins via ubiquitination and non-proteolytic mechanisms. However, its role in osteosarcoma pathogenesis and association with patient prognosis remain poorly understood.
Methods
We integrated bioinformatics analyses of public databases with assayal validation in osteosarcoma cell lines and clinical tissue samples to assess RNF207 expression and its prognostic significance. Functional assays were performed to evaluate the impact of RNF207 knockdown or overexpression on osteosarcoma cell proliferation, migration, and invasion. Mechanistic insights were investigated through transcriptomic profiling, mass spectrometry, and co-immunoprecipitation assays. Finally, subcutaneous xenograft models were employed to validate RNF207's role in osteosarcoma progression in vivo.
Results
RNF207 was significantly upregulated in osteosarcoma cells and clinical specimens and correlated with adverse clinical outcomes. Genetic silencing of RNF207 suppressed osteosarcoma cell proliferation, migration, and invasion, whereas its overexpression enhanced these malignant phenotypes. Furthermore, RNF207 knockdown attenuated tumor growth in subcutaneous xenograft models. Mechanistically, RNF207 facilitated ubiquitin-mediated degradation of KCNQ1, thereby potentiating MAPK signaling pathway activation.
Conclusion
Clinically, elevated RNF207 expression in osteosarcoma patients serves as a biomarker for aggressive disease and unfavorable prognosis. Functionally, RNF207 drives osteosarcoma progression in vitro and in vivo by ubiquitinating and degrading KCNQ1 to hyperactivate MAPK signaling. These findings identify RNF207 as a novel therapeutic target and prognostic marker for osteosarcoma.
期刊介绍:
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.
The subject material appropriate for submission includes:
• Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
• Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.
• Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.
• Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.
• Agents that activate genes or modify transcription and translation within the immune response.
• Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.
• Production, function and regulation of cytokines and their receptors.
• Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.